THIQ is a drug used in scientific research, which is the first non-peptide agonist developed that is selective for the melanocortin receptor subtype MC4. In animal studies, THIQ stimulated sexual activity in rats, but with little effect on appetite or inflammation. This supports possible application of MC4 selective agonists for the treatment of sexual dysfunction in humans, although THIQ itself has poor oral bioavailability and a short duration of action so improved analogues will need to be developed.
^Mutulis F, Yahorava S, Mutule I, Yahorau A, Liepinsh E, Kopantshuk S, Veiksina S, Tars K, Belyakov S, Mishnev A, Rinken A, Wikberg JE (August 2004). "New substituted piperazines as ligands for melanocortin receptors. Correlation to the X-ray structure of "THIQ"". Journal of Medicinal Chemistry. 47 (18): 4613–26. PMID15317471. doi:10.1021/jm0311285.
^Martin WJ, McGowan E, Cashen DE, Gantert LT, Drisko JE, Hom GJ, Nargund R, Sebhat I, Howard AD, Van der Ploeg LH, MacIntyre DE (November 2002). "Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula". European Journal of Pharmacology. 454 (1): 71–9. PMID12409007. doi:10.1016/S0014-2999(02)02479-2.
^Muceniece R, Zvejniece L, Vilskersts R, Liepinsh E, Baumane L, Kalvinsh I, Wikberg JE, Dambrova M (December 2007). "Functional evaluation of THIQ, a melanocortin 4 receptor agonist, in models of food intake and inflammation". Basic & Clinical Pharmacology & Toxicology. 101 (6): 416–20. PMID18028105. doi:10.1111/j.1742-7843.2007.00133.x.
^Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ (2007). "Melanocortins in the treatment of male and female sexual dysfunction". Current Topics in Medicinal Chemistry. 7 (11): 1137–44. PMID17584134. doi:10.2174/156802607780906681.